Using racemic sulpiride as a reference drug, we assessed the usefulness of levosulpiride (the levo-isomer of sulpiride) in the management of non-ulcer dyspepsia. In this double-blind, randomized study, 50 patients with non-ulcer dyspepsia received 25 mg of levosulpiride or 50 mg of racemic sulpiride three times daily for 30 days. Symptomatic improvement was evaluated by interview at the end of the study. Globally, a good or excellent result was obtained in both groups (P <0.01) with no statistical difference. Levosulpiride markedly reduced the severity of anorexia, nausea, postprandial fullness, belching, and epigastric pain without significant side effects. The results suggest that levosulpiride, at 25 mg TID, is effective in the treatment of chronic functional dyspepsia.
|Number of pages||5|
|Journal||Current Therapeutic Research|
|Publication status||Published - 1992|
ASJC Scopus subject areas